Reports
Reports
Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer cells removed during the biopsy are examined to check the presence of progesterone or estrogen receptor proteins.
The hormones, i.e. estrogen and progesterone, encourage cancer growth when they bind to these receptors. If these receptors are present, cancers are classified as hormone receptor-positive or hormone receptor-negative.
Breast cancer develops due to BRCA gene mutation, PIK3CA gene mutation, etc. Ducts and lobules are the major components of a breast, and everything is held together by the connective tissue that surrounds it. Breast cancer develops where the ducts or lobules are located, and it can spread to the other body parts via blood and lymph arteries.
Breast cancer is metastasized when it spreads to the other body regions. Advanced breast cancer is another word for metastatic breast cancer. Advanced breast cancer is defined in medical terms as breast cancer that has gone beyond the breast to the other essential organs in the body, such as the bones, lungs, liver, or brain, to mention a few.
Metastatic breast cancer usually develops months or years after a person has finished treatment for an early or locally advanced variety of breast cancer, such as stage I, II, or III. As a result, metastatic breast cancer is also known as distant recurrence.
According to the American Cancer Society, in 2024, around 310,720 new invasive breast cancers and 56,500 cases of ductal carcinoma in situ were diagnosed among the women in the U.S., and an additional 2,790 cases were diagnosed in men.
Workplace stress has increased as a result of the fast-paced corporate culture, with work from home post COVID-19 adding fuel to the fire. Furthermore, people's sedentary lifestyles have resulted in various health problems. The prevalence of breast cancer has increased due to these factors, which will boost the market for breast cancer therapies.
Breast cancer cases have also increased due to lack of exercise, overstressed daily schedule, and denying the health issues. According to SUSAN G. KOMEN, more than 287,000 new instances of invasive breast cancer were identified in women and 2,700 cases in men in the United States in 2022, with almost 44,000 women and men expected to die from breast cancer in the United States.
If the breast cancer location is discovered and treated early the disease can be cured. According to the National Library of Medicine, stage 4 breast cancer survival rate by age of 50 has a higher recovery rate than older women. Approximately 13% of women diagnosed with stage IV breast cancer live for ten years after their diagnosis. Considering all of these factors, demand for breast cancer medicines has boosted the worldwide breast cancer therapeutics market.
Also, it has led to the advent of various therapies like tumor-agnostic treatment, HER2-targeted therapy, ovarian suppression, whole brain radiation therapy, immunotherapy, stereotactic radiosurgery, fractionated stereotactic radiation therapy, which are ultimately contributing to the growth of the industry.
Many major players in the breast cancer therapeutics market invest in research and development activities to develop novel medications and treatment strategies (e.g., blood test for tumour markers) for the disease.
A spike in the number of breast cancer patients has increased the demand for better screening, diagnosis and therapy. Breast cancer is diagnosed most frequently among American women. According to breastcancer.org, breast cancer will account for around 30% of newly diagnosed malignancies in women by 2022.
Furthermore, as of 2021, breast cancer was the most frequent cancer worldwide, accounting for 12% of all new cancer cases. The general public's knowledge of breast cancer is growing, which has boosted sales of various cancer treatment drugs like tamoxifen, fulvestrant (faslodex), capecitabine, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, aromatase inhibitors, pegylated, epirubicin, eribulin, fluorouracil, gemcitabine, ixabepilone, methotrexate, nab-paclitaxel, paclitaxel, vinorelbine.
The increased investments in research & development activities and increasing cancer diagnostics awareness campaigns are expected to assist this market to grow significantly in the upcoming years.
In the case of postmenopausal women with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, ribociclib plus endocrine therapy have showed a significant overall survival benefit, according to a randomized phase 3 trial funded by Novartis. Initially, the findings were presented at the European Society for Medical Oncology Congress 2021 and communicated through The New England Journal of Medicine.
The market is also expected to rise as reimbursement policies have improved significantly. Due to the vast patient pool, government initiatives, and government financing to discover innovative medicines and improve healthcare conditions, the Asia-Pacific’s market is predicted to grow at the fastest rate.
Breast cancer samples collected from women under 45 years of age were subjected to a genetic study by University of Melbourne researchers recently. They've discovered a new pharmacological target to help these young ladies have a better prognosis. The Morrison government is giving more than US$ 4.9 Mn to researchers for a clinical trial to assess these novel medicines.
Furthermore, University of Novel South Wales researchers are focusing on treatment-resistant triple-negative breast cancer, where new medicines are desperately needed to increase survival rates. The researchers will test this new medicine in a clinical trial with over $670,000 in government financing.
Chemotherapy is the dominant segment in the metastatic breast cancer market as it helps in slowing the tumor’s growth.
According to Cancer World magazine, the number of patients requiring first-line chemotherapy would grow by 53% (from 9.8 million in 2018 to 15 million in 2040). 67% of these patients (10.1 million) will live in low- and middle-income countries by 2040. Chemotherapy was necessary in 57.7% of new cancer cases (9.8 million out of 17 million) worldwide in 2018. In 2040, there will be 26 million new cancer cases, with 53% (15 million) of those requiring chemotherapy (an increase of 5.2 million new cancer cases from 2018). Chemotherapy is more frequently used to treat breast cancers in the middle or late stages.
The five-year survival rate for patients diagnosed in stage 1 is around 90%. The 5-year life expectancy for breast cancer patients identified at stage 4 is 26%. Hormone therapy for premenopausal women is becoming the most popular treatment since it slows cancer cell proliferation. The market share of the metastatic breast cancer industry is predicted to expand due to this therapy.
North America dominated the global market in 2024 by accounting for around 42.3% share. In addition, countries such as the United States, are pushing breast cancer patient awareness programs, which is projected to contribute to the region's industry growth.
As the incidence of cancer rises, the need for metastatic breast cancer therapy in North American countries is likely to rise. Breast cancer impacts more than 4.1 million American women, according to the Breast Cancer Organization's data as of January 2024.
According to statistics, breast cancer is expected to account for roughly 30% of newly diagnosed cancers among women in 2024.
NA
NA
NA
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Metastatic Breast Cancer Market
